RVL Pharmaceuticals plc Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from Q3 2017 to Q2 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
RVL Pharmaceuticals plc quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q3 2017 to Q2 2023.
- RVL Pharmaceuticals plc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending June 30, 2023 was -$24M, a 103% decline year-over-year.
- RVL Pharmaceuticals plc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending June 30, 2023 was -$68.5M, a 4.47% decline year-over-year.
- RVL Pharmaceuticals plc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$51.7M, a 37.3% increase from 2021.
- RVL Pharmaceuticals plc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was -$82.5M, a 12.9% increase from 2020.
- RVL Pharmaceuticals plc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2020 was -$94.8M, a 28.6% increase from 2019.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)